Terminated
PHASE2
INTERVENTIONAL
NCT00997152
Efficacy and Safety Study of JTT-654 in Type 2 Diabetic Patients
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The purpose of this study is to evaluate the effect of JTT-654 on diabetes as well as the safety, tolerability and pharmacokinetics of JTT-654 in type 2 diabetic patients.
Interventions
Name:
JTT-654
Type:
DRUG
Description:
Tablets
Name:
JTT-654 Placebo
Type:
DRUG
Description:
Tablets
Primary Outcomes
Measure:
Change in Fasting Plasma Glucose (FPG) levels
TimeFrame:
3 months
Description:
Trial Information
NCT ID
NCT00997152
Status
Terminated
Study Type
INTERVENTIONAL
Phases
PHASE2
Sponsor
Akros Pharma Inc.
Last Updated
December 15, 2025